Vera Therapeutics wins FDA nod for closely watched kidney disease drug

The clearance marks another step forward in treatment for IgA nephropathy and sets up a commercial battle with Otsuka, which brought a similar medication to market last year. 

By Delilah Alvarado • July 7, 2026

Gene editing developer Scribe plots an IPO

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.

By Gwendolyn Wu • July 6, 2026

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Novartis to acquire ADC developer in a deal worth up to $1.5B

The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.

By Delilah Alvarado • July 6, 2026

Cancer, immune drugmakers dominate VC funding so far in 2026

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.

By Gwendolyn Wu • July 6, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

A PureTech startup banks $180M for a new IPF drug

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.

By Gwendolyn Wu • July 2, 2026

Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal

The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.

By Kristin Jensen • July 1, 2026

Abivax shares surge as worries subside over immune drug’s cancer risk

According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.

By Jonathan Gardner • July 1, 2026

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.

By BioPharma Dive staff • June 30, 2026

Viridian may have edge over Amgen in eye drug showdown, analysts argue

The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.

By Delilah Alvarado • June 30, 2026

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

By Kelly Bilodeau • June 30, 2026

Beeline ups its Series A round for immune drug work

The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.

By Gwendolyn Wu • June 30, 2026

Theravance, after clinical setbacks, agrees to $929M buyout

The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.

By Jonathan Gardner • June 29, 2026

10 clinical trials to watch in the second half of 2026

The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.

By BioPharma Dive staff • June 29, 2026

FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.

By BioPharma Dive staff • June 26, 2026

At BIO, tension over China biotech deal regulation looms

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.

By Gwendolyn Wu • Updated July 1, 2026

Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.

By Jacob Bell • June 26, 2026

On second try, Acadia drug gets nod from European regulators

The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

By Jonathan Gardner • June 26, 2026

Antares gets $105M from Novartis for new cancer drugs

Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."

By Gwendolyn Wu • June 25, 2026

Ionis, with new FDA nod, hits a ‘commercial inflection point’

Historically seen as a "platform monetization story," according to one analyst, Ionis now has a potential multibillion-dollar medicine in Tryngolza, which secured expanded approval Wednesday.

By Delilah Alvarado • June 24, 2026

Investors pour $115M into RQ Bio in search of a preventive flu drug

The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza strains.

By Delilah Alvarado • June 24, 2026

To Wall Street, psychedelics biotechs are more teammates than rivals

Some analysts argue that, even for competitors, a big clinical trial win for Definium Therapeutics helps validate the psychedelic field and “bring it even further into the mainstream.”

By Jacob Bell • June 24, 2026

Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor

Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230 million to a gene editing startup and Merck KGaA struck a “build-to-buy” deal.

By Ben Fidler • June 24, 2026

Ollin refuels with $330M to back pivotal tests of Vabysmo challenger

One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over Roche’s eye treatment.

By Kristin Jensen • June 24, 2026

How Kardigan spun deal leftovers into a $400M IPO

CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX's huge public offering didn't hurt either.

By Jacob Bell • June 23, 2026